Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of HRS9531 in Hepatic Impairment
NCT07540754Phase 1Recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS9531 in diabetes mellitus (DM) (3 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Maximum concentration, Area under the concentration-time curve to the last measurable concentration and 1 more. Started May 2026; status: recruiting.
02
Drugs
HRS9531
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT07540754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540754.